Sharecast reports that biotech industry sponsor Angle announced that its metastatic breast cancer trial was now complete thanks to the significant efforts of four U.S. cancer centers including:
- University of Texas MD Anderson Cancer Center
- University of Southern California Norris Cancer Center
- University of Rochester Wilmot Cancer Center
- Northwestern University, Robert H Lurie Cancer Center
The four research centers greatly aided the sponsor in recruiting 400 studies to help complete the overall study. These prominent centers will now conduct downstream analyses of samples; the sponsor seeks a submission to the FDA by mid-2019. Called the Parsotix FDA clinical study, Angle founder and CEO Andrew Newland reports this is a key milestone for the company.
Angle plc was founded in 1994. It is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and fetal health.